T

T-Therapeutics

T-Therapeutics is a biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) therapeutics for cancer and autoimmune diseases. They have raised $133 million in Series B funding to advance their first-in-class TCR-CD3 bispecific programs through clinical proof-of-concept. The company's proprietary OpTiMus® platform enables access to previously undruggable intracellular targets.

Total raised
Undisclosed
tracked to date
Latest round
Series B
Nov 8, 2026
Known investors
8
led by Advent Life Sciences

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United Kingdom.

Claim this profile →

🏆 Featured in Datapile’s Q4 2026 UK Funding Report

Read the Q4 2026 UK report →
Add this badge to your site
<a href="https://datapile.co/reports/q4-2026-uk-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q4 2026 UK Funding Report</a>

Funding history

  1. 1
    $133 million Series BSeries BNov 8, 2026

    Led by Advent Life Sciences

    Announcement ↗

Investors in T-Therapeutics

Backers from this company's tracked funding rounds.

  • AAdvent Life SciencesLead investorVC firm
  • BBritish Business BankVC firm
  • JJohnson & Johnson Innovation – JJDC, Inc. (JJDC)VC firm
  • SSamsara BioCapitalVC firm
  • MM-VenturesVC firm
  • EEli Lilly and Company (Lilly)VC firm
  • SSofinnova PartnersVC firm
  • FF-PrimeVC firm

T-Therapeutics in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile